Edwards Lifesciences Corp... (EW)
Edwards Lifesciences Statistics
Share Statistics
Edwards Lifesciences has 587.9M shares outstanding. The number of shares has increased by -1.91% in one year.
| Shares Outstanding | 587.9M |
| Shares Change (YoY) | -1.91% |
| Shares Change (QoQ) | -2.09% |
| Owned by Institutions (%) | 83.92% |
| Shares Floating | 576.41M |
| Failed to Deliver (FTD) Shares | 1.08K |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 9.04M, so 1.53% of the outstanding shares have been sold short.
| Short Interest | 9.04M |
| Short % of Shares Out | 1.53% |
| Short % of Float | 1.56% |
| Short Ratio (days to cover) | 1.81 |
Valuation Ratios
The PE ratio is 10.6 and the forward PE ratio is 29.66. Edwards Lifesciences's PEG ratio is 0.05.
| PE Ratio | 10.6 |
| Forward PE | 29.66 |
| PS Ratio | 8.13 |
| Forward PS | 4.9 |
| PB Ratio | 4.43 |
| P/FCF Ratio | 152.63 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Edwards Lifesciences Corporation has an Enterprise Value (EV) of 45.81B.
| EV / Earnings | 10.97 |
| EV / Sales | 8.42 |
| EV / EBITDA | 26.59 |
| EV / EBIT | 33.23 |
| EV / FCF | 158.03 |
Financial Position
The company has a current ratio of 4.18, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.18 |
| Quick Ratio | 3.45 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.54 |
| Cash Flow / Debt | 0.77 |
| Interest Coverage | 69.63 |
Financial Efficiency
Return on equity (ROE) is 0.42% and return on capital (ROIC) is 11.55%.
| Return on Equity (ROE) | 0.42% |
| Return on Assets (ROA) | 0.32% |
| Return on Capital (ROIC) | 11.55% |
| Revenue Per Employee | $344,272.15 |
| Profits Per Employee | $264,215.19 |
| Employee Count | 15,800 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.03 |
Taxes
| Income Tax | 152.1M |
| Effective Tax Rate | 0.1 |
Stock Price Statistics
The stock price has increased by -24.95% in the last 52 weeks. The beta is 1.12, so Edwards Lifesciences's price volatility has been higher than the market average.
| Beta | 1.12 |
| 52-Week Price Change | -24.95% |
| 50-Day Moving Average | 71.51 |
| 200-Day Moving Average | 73.06 |
| Relative Strength Index (RSI) | 49.75 |
| Average Volume (20 Days) | 4.55M |
Income Statement
In the last 12 months, Edwards Lifesciences had revenue of 5.44B and earned 4.17B in profits. Earnings per share was 6.98.
| Revenue | 5.44B |
| Gross Profit | 4.32B |
| Operating Income | 1.38B |
| Net Income | 4.17B |
| EBITDA | 1.72B |
| EBIT | 1.38B |
| Earnings Per Share (EPS) | 6.98 |
Balance Sheet
The company has 3.05B in cash and 700M in debt, giving a net cash position of 2.35B.
| Cash & Cash Equivalents | 3.05B |
| Total Debt | 700M |
| Net Cash | 2.35B |
| Retained Earnings | 13.17B |
| Total Assets | 13.06B |
| Working Capital | 4.78B |
Cash Flow
In the last 12 months, operating cash flow was 542.3M and capital expenditures -252.4M, giving a free cash flow of 289.9M.
| Operating Cash Flow | 542.3M |
| Capital Expenditures | -252.4M |
| Free Cash Flow | 289.9M |
| FCF Per Share | 0.49 |
Margins
Gross margin is 79.46%, with operating and profit margins of 25.35% and 76.75%.
| Gross Margin | 79.46% |
| Operating Margin | 25.35% |
| Pretax Margin | 28.46% |
| Profit Margin | 76.75% |
| EBITDA Margin | 31.68% |
| EBIT Margin | 25.35% |
| FCF Margin | 5.33% |
Dividends & Yields
EW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 9.92% |
| FCF Yield | 0.7% |
Analyst Forecast
The average price target for EW is $78, which is 10.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $78 |
| Price Target Difference | 10.8% |
| Analyst Consensus | Hold |
| Analyst Count | 21 |
Stock Splits
The last stock split was on Jun 1, 2020. It was a forward split with a ratio of 3:1.
| Last Split Date | Jun 1, 2020 |
| Split Type | forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | 11.07 |
| Piotroski F-Score | 6 |